ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

SNGX Soligenix Inc

0.3531
-0.0059 (-1.64%)
2024年5月25日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Soligenix Inc SNGX NASDAQ 普通株式
  前日比 前日比 % 現在値 時刻
-0.0059 -1.64% 0.3531 13:00:11
始値 安値 高値 終値 前日終値
0.36 0.3212 0.39 0.365 0.359
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/5/2505:05EDGAR2Form 8-K - Current report
2024/5/2420:30PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2024/5/2320:30PRNUSSoligenix Encourages Stockholders to Vote "FOR" Reverse..
2024/5/2305:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2024/5/2201:35GLOBEPRISM MarketView Highlights Soligenix, Inc. as it Builds on..
2024/5/2120:30PRNUSSuVax™ and MarVax™ Thermostable Vaccine Platform to be..
2024/5/2020:30PRNUSSoligenix Encourages Stockholders to Vote Prior to Annual..
2024/5/1805:25EDGAR2Form 8-K - Current report
2024/5/1805:09EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2024/5/1620:30PRNUSPositive Clinical Results from HyBryte™ Compatibility Study..
2024/5/1605:05EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2024/5/1105:16EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
2024/5/1105:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/5/1020:30PRNUSSoligenix Announces Recent Accomplishments And First Quarter..
2024/5/0620:30PRNUSSoligenix to Present at Upcoming Conferences
2024/4/2520:30PRNUSSoligenix Extends Patent Protection for its Filovirus..
2024/4/1821:30PRNUSSoligenix Announces Pricing of $4.75 Million Public Offering
2024/4/1520:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
2024/4/1120:30PRNUSFDA Grants Soligenix Orphan Drug Designation for the..
2024/4/0320:30PRNUSSoligenix Announces Agreement on the Design of a Second..
2024/3/1520:30PRNUSSoligenix Announces Recent Accomplishments and Year End 2023..
2024/2/0821:30PRNUSSoligenix Announces Formation of Behçet's Disease Medical..
2024/1/2521:30PRNUSSoligenix to Present at The Microcap Conference
2024/1/0821:30PRNUSFDA Grants Soligenix "Fast Track" Designation for Dusquetide..
2024/1/0421:30PRNUSSoligenix Announces Top-line Results of the Phase 2a Study..
2024/1/0221:30PRNUSSoligenix Announces Publication Demonstrating Complete..
2023/12/2306:05EDGAR2Form 8-K - Current report
2023/12/1814:15EDGAR2Form EFFECT - Notice of Effectiveness
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/1606:03EDGAR2Form 8-K - Current report
2023/12/0907:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0907:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2023/12/0906:05EDGAR2Form S-3/A - Registration statement under Securities Act of..
2023/12/0121:30PRNUS"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma"..
2023/11/3021:30PRNUSSoligenix Receives FDA IND Clearance for Phase 2 Clinical..
2023/11/1806:05EDGAR2Form 8-K - Current report
2023/11/1806:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2023/11/1406:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/1321:30PRNUSSoligenix Announces Recent Accomplishments And Third Quarter..
2023/10/2105:05EDGAR2Form 8-K - Current report
2023/10/2105:00PRNUSSoligenix, Inc. Announces Adjournment of Annual Meeting,..
2023/10/1802:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1802:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1705:45EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
2023/10/1620:30PRNUSSoligenix to Present at The ThinkEquity Conference

最近閲覧した銘柄

Delayed Upgrade Clock